Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review

References

• World Health Organization, Geneva Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications Report of a WHO Consultation World Health Organization Department of Noncommunicable Disease Surveillance 1999
   Google Scholar
• Roglic G Unwin N Bennett PH The burden of mortality attributable to diabetes: realistic estimates for the year 2000 Diabetes Care 2005 28 2130 2135 16123478
   PubMed Web of Science ®Google Scholar
• Wild S Roglic G Green A Sicree R King H Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 Diabetes Care 2004 27 1047 1053 15111519
   PubMed Web of Science ®Google Scholar
• King H Aubert RE Herman WH Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections Diabetes Care 1998 21 1414 1431 9727886
   PubMed Web of Science ®Google Scholar
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) UK Prospective Diabetes Study (UKPDS) Group Lancet 1998 352 837 853 9742976
   PubMed Web of Science ®Google Scholar
• Gaede P Lund-Andersen H Parving HH Pedersen O Effect of a multifactorial intervention on mortality in type 2 diabetes N Engl J Med 2008 358 580 591 18256393
   PubMed Web of Science ®Google Scholar
• Patel A MacMahon S Chalmers J Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 2008 358 2560 2572 18539916
   PubMed Web of Science ®Google Scholar
• Gerstein HC Miller ME Byington RP Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 2008 358 2545 2559 18539917
   PubMed Web of Science ®Google Scholar
• Duckworth W Abraira C Moritz T Glucose control and vascular complications in veterans with type 2 diabetes N Engl J Med 2009 360 129 139 19092145
   PubMed Web of Science ®Google Scholar
• Nathan DM Buse JB Davidson MB Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes Diabetologia 2009 52 17 30 18941734
   PubMed Web of Science ®Google Scholar
• Bolen S Feldman L Vassy J Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus Ann Intern Med 2007 147 386 399 17638715
   PubMed Web of Science ®Google Scholar
• Maedler K Carr RD Bosco D Zuellig RA Berney T Donath MY Sulfonylurea induced beta-cell apoptosis in cultured human islets J Clin Endocrinol Metab 2005 90 501 506 15483097
   PubMed Web of Science ®Google Scholar
• Holst JJ The physiology of glucagon-like peptide 1 Physiol Rev 2007 87 1409 1439 17928588
   PubMed Web of Science ®Google Scholar
• Nauck MA Homberger E Siegel EG Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses J Clin Endocrinol Metab 1986 63 492 498 3522621
   PubMed Web of Science ®Google Scholar
• Brown JC Mutt V Pederson RA Further purification of a polypeptide demonstrating enterogastrone activity J Physiol 1970 209 57 64 5499047
   PubMed Web of Science ®Google Scholar
• Deacon CF Johnsen AH Holst JJ Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo J Clin Endocrinol Metab 1995 80 952 957 7883856
   PubMed Web of Science ®Google Scholar
• Vilsboll T Agerso H Lauritsen T The elimination rates of intact GIP as well as its primary metabolite, GIP 3–42, are similar in type 2 diabetic patients and healthy subjects Regul Pept 2006 137 168 172 16934887
   PubMed Web of Science ®Google Scholar
• Drucker DJ The biology of incretin hormones Cell Metab 2006 3 153 165 16517403
   PubMed Web of Science ®Google Scholar
• Orskov C Holst JJ Poulsen SS Kirkegaard P Pancreatic and intestinal processing of proglucagon in man Diabetologia 1987 30 874 881 3446554
   PubMed Web of Science ®Google Scholar
• Orci L Bordi C Unger RH Perrelet A Glucagon- and glicentin-producing cells Lefebvre PJ Glucagon Berlin Springer Verlag 1983 57 79
   Google Scholar
• Goke R Larsen PJ Mikkelsen JD Sheikh SP Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites Eur J Neurosci 1995 7 2294 2300 8563978
   PubMed Web of Science ®Google Scholar
• Flint A Raben A Astrup A Holst JJ Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans J Clin Invest 1998 101 515 520 9449682
   PubMed Web of Science ®Google Scholar
• Gros R You X Baggio LL Cardiac function in mice lacking the glucagon- like peptide-1 receptor Endocrinology 2003 144 2242 2252 12746281
   PubMed Web of Science ®Google Scholar
• Meier JJ Gethmann A Gotze O Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans Diabetologia 2006 49 452 458 16447057
   PubMed Web of Science ®Google Scholar
• Carraro-Lacroix LR Malnic G Girardi AC Regulation of Na+/H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells Am J Physiol Renal Physiol 2009 297 F1647 F1655 19776173
   PubMed Web of Science ®Google Scholar
• Gault VA O’Harte FP Flatt PR Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential? Neuropeptides 2003 37 253 263 14607102
   PubMed Web of Science ®Google Scholar
• Tsukiyama K Yamada Y Yamada C Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion Mol Endocrinol 2006 20 1644 1651 16469773
   PubMed Web of Science ®Google Scholar
• Knop FK Vilsboll T Hojberg PV Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes 2007 56 1951 1959 17513701
   PubMed Web of Science ®Google Scholar
• Nauck M Stockmann F Ebert R Creutzfeldt W Reduced incretin effect in type 2 (non-insulin-dependent) diabetes Diabetologia 1986 29 46 52 3514343
   PubMed Web of Science ®Google Scholar
• Bagger JO Knop FK Lund A Vestergaard H Holst JJ Vilsboll T Impaired Regulation of the Incretin Effect in Patients with Type 2 Diabetes Mellitus Diabetes 2010 58 Suppl 1 A369
   Google Scholar
• Vilsboll T Krarup T Deacon CF Madsbad S Holst JJ Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients Diabetes 2001 50 609 613 11246881
   PubMed Web of Science ®Google Scholar
• Kjems LL Holst JJ Volund A Madsbad S The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects Diabetes 2003 52 380 386 12540611
   PubMed Web of Science ®Google Scholar
• Nauck MA Heimesaat MM Orskov C Holst JJ Ebert R Creutzfeldt W Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus J Clin Invest 1993 91 301 307 8423228
   PubMed Web of Science ®Google Scholar
• Nauck MA Kleine N Orskov C Holst JJ Willms B Creutzfeldt W Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7–36 amide) in type 2 (non-insulin-dependent) diabetic patients Diabetologia 1993 36 741 744 8405741
   PubMed Web of Science ®Google Scholar
• Eng J Kleinman WA Singh L Singh G Raufman JP Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas J Biol Chem 1992 267 7402 7405 1313797
   PubMed Web of Science ®Google Scholar
• Thorens B Porret A Buhler L Deng SP Morel P Widmann C Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9–39) an antagonist of the receptor Diabetes 1993 42 1678 1682 8405712
   PubMed Web of Science ®Google Scholar
• Edwards CM Stanley SA Davis R Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers Am J Physiol Endocrinol Metab 2001 281 E155 E161 11404233
   PubMed Web of Science ®Google Scholar
• Simonsen L Holst JJ Deacon CF Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs Diabetologia 2006 49 706 712 16447056
   PubMed Web of Science ®Google Scholar
• Malloy J Capparelli E Gottschalk M Guan X Kothare P Fineman M Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study Clin Ther 2009 31 806 815 19446153
   PubMed Web of Science ®Google Scholar
• Iwamoto K Nasu R Yamamura A Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes Endocr J 2009 56 951 962 19706990
   PubMed Web of Science ®Google Scholar
• European medicines Agency European Public Assessment Report Byetta EMEA/H/C/698 2006
   Google Scholar
• Knudsen LB Nielsen PF Huusfeldt PO Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration J Med Chem 2000 43 1664 1669 10794683
   PubMed Web of Science ®Google Scholar
• Elbrond B Jakobsen G Larsen S Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects Diabetes Care 2002 25 1398 1404 12145241
   PubMed Web of Science ®Google Scholar
• Damholt B Golor G Wierich W Pedersen P Ekblom M Zdravkovic M An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide J Clin Pharmacol 2006 46 635 641 16707410
   PubMed Web of Science ®Google Scholar
• Bosi E Lucotti P Setola E Monti L Piatti PM Incretin-based therapies in type 2 diabetes: A review of clinical results Diabetes Res Clin Pract 2008 82 Suppl 2 S102 S107 19022515
   PubMed Web of Science ®Google Scholar
• DeFronzo RA Ratner RE Han J Kim DD Fineman MS Baron AD Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes Diabetes Care 2005 28 1092 1100 15855572
   PubMed Web of Science ®Google Scholar
• Buse JB Henry RR Han J Kim DD Fineman MS Baron AD Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes Diabetes Care 2004 27 2628 2635 15504997
   PubMed Web of Science ®Google Scholar
• Kendall DM Riddle MC Rosenstock J Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea Diabetes Care 2005 28 1083 1091 15855571
   PubMed Web of Science ®Google Scholar
• Amori RE Lau J Pittas AG Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis JAMA 2007 298 194 206 17622601
   PubMed Web of Science ®Google Scholar
• Heine RJ Van Gaal LF Johns D Mihm MJ Widel MH Brodows RG Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial Ann Intern Med 2005 143 559 569 16230722
   PubMed Web of Science ®Google Scholar
• Nauck MA Duran S Kim D A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study Diabetologia 2007 50 259 267 17160407
   PubMed Web of Science ®Google Scholar
• Zinman B Hoogwerf BJ Duran GS The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial Ann Intern Med 2007 146 477 485 17404349
   PubMed Web of Science ®Google Scholar
• Klonoff DC Buse JB Nielsen LL Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years Curr Med Res Opin 2008 24 275 286 18053320
   PubMed Web of Science ®Google Scholar
• Klonoff DC Buse JB Nielsen LL Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years Curr Med Res Opin 2008 24 275 286 18053320
   PubMed Web of Science ®Google Scholar
• Okerson T Yan P Stonehouse A Brodows R Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes Am J Hypertens 2010 23 334 339 20019672
   PubMed Web of Science ®Google Scholar
• Garber A Henry R Ratner R Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial Lancet 2009 373 473 481 18819705
   PubMed Web of Science ®Google Scholar
• Garber A Henry R Ratner R Hale PM Chang CT Bode B Liraglutide, a human GLP-1 analogue, maintains greater reductions in HbA1c, FPG and weight than glimepiride over 2 years in patients with type 2 diabetes: LEAD-3 extension study Diabetologia 2010 52 Suppl 1 S287
   Google Scholar
• Nauck MA Frid A Hermansen K for the LEAD-2 Metformin Study Group Efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes mellitus Diabetes Care 2009 32 84 90 18931095
   PubMed Web of Science ®Google Scholar
• Marre M Shaw J Brandle M Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU) Diabet Med 2009 26 268 278 19317822
   PubMed Web of Science ®Google Scholar
• Zinman B Gerich J Buse JB Efficacy and safety of the human glucagon- like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD) Diabetes Care 2009 32 1224 1230 19289857
   PubMed Web of Science ®Google Scholar
• Russell-Jones D Vaag A Schmitz O Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): a randomised controlled trial Diabetologia 2009 52 2046 2055 19688338
   PubMed Web of Science ®Google Scholar
• Buse JB Rosenstock J Sesti G Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) Lancet 2009 374 39 47 19515413
   PubMed Web of Science ®Google Scholar
• European medicines Agency European Public Assessment Report Victoza EMEA/H/C/1026 2009
   Google Scholar
• Blonde L Russell-Jones D The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1–5 studies Diabetes Obes Metab 2009 11 Suppl 3 26 34 19878259
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration Information for Healthcare Professionals Exenatide (marketed as Byetta) [press release] 2009 http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124713.htm
   Google Scholar
• Cvetkovic RS Plosker GL Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea) Drugs 2007 67 935 954 17428109
   PubMed Web of Science ®Google Scholar